Why Shattuck Labs Stock Soared in December

Group 1 - Shattuck Labs has shown significant progress in the early development of its investigational drug SL-325, supported by fresh capital [1][9] - The stock price of Shattuck Labs rose by nearly 74% following an upgrade from H.C. Wainwright's analyst Joseph Pantginis, who set a new price target of $6 per share [2][6] - SL-325 is a first-in-class antagonist antibody targeting inflammatory and immune-mediated disorders, currently being evaluated for irritable bowel syndrome (IBS) [4][8] Group 2 - The analyst noted that SL-325 has potential efficacy for multiple indications beyond IBS and expressed optimism about the company's overall pipeline [5] - Shattuck Labs raised approximately $103 million in a private funding round, which is expected to support operations through 2029 [9] - The company reported a reduced net loss of slightly more than $10 million in Q3, down from nearly $17 million in the same period of 2024, indicating improved financial discipline [10]